Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Public ClinicalTrials.gov record NCT05669833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Study identification
- NCT ID
- NCT05669833
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2023 (Actual)
- Primary completion
- Oct 26, 2026 (Actual)
- Completion
- Jan 2027 (Estimated)
- Last update posted
- Nov 5, 2026
2023 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Family Arthritis Center | Loxahatchee Groves | Florida | 33470 | — |
| Healing Rheumatology | Plant City | Florida | 33563 | — |
| Southwest Florida Rheumatology | Riverview | Florida | 33569 | — |
| Parris and Associates | Lilburn | Georgia | 30047 | — |
| University of Massachusetts Chan Medical School | Worcester | Massachusetts | 01655 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| New York University | New York | New York | 10016 | — |
| Cincy Arthritis | Blue Ash | Ohio | 45242 | — |
| Southern Ohio Rheumatology | Wheelersburg | Ohio | 45694 | — |
| Hospital at the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Cumberland Rheumatology | Crossville | Tennessee | 38555 | — |
| Heritage Rheumatology and Arthritis Care | Colleyville | Texas | 76034 | — |
| Texas Arthritis Center | El Paso | Texas | 79902 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05669833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2026 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05669833 live on ClinicalTrials.gov.